INTRODUCTION

Heavy menstrual bleeding (HMB) is a common problem that can significantly affect women’s lives until menopause. Although diagnostic definitions using menstrual blood loss exist, it is the impact on a woman’s physical, emotional, social, and economic quality of life that guides treatment.1,2

In 2007, the National Institute for Health and Care Excellence (NICE) published guidelines for HMB, updating them in 2018. These recommend starting medical treatment for HMB without investigation if history and/or examination suggest low risk of uterine pathology; or taking account of history and examination, following ultrasound and/or hysteroscopy to exclude this. The levonorgestrel-releasing intrauterine system (LNG-IUS) is recommended as first-line treatment for women with no uterine pathology, or the use of other medical treatments if LNG-IUS is declined or not suitable (tranexamic acid, non-steroidal anti-inflammatory drugs, combined hormonal contraception, oral progesterogens).1 NICE emphasises clinical consideration be given to comorbidities, presence of fibroids, adenomyosis or endometrial polyps, contraceptive need, and women’s preferences for first-line treatment. If medical treatments fail to provide effective relief, surgical procedures should be considered.3

The NICE recommendations were supported by findings from the original ECLIPSE trial, which randomised 571 women, aged 25 to 50 years, presenting to primary care with HMB to either the LNG-IUS or other usual medical treatment (oral tranexamic acid, mefenamic acid, combined oral contraceptive pill, or progesterone alone, chosen as clinically appropriate by the GP and woman) (ISRCTN86566246).1,3 Women’s eligibility for the original trial, and their clinical assessment consistent with current NICE guidance, are detailed in the Supplementary Information S1. The primary outcome was a patient-reported score of the burden of HMB,4 assessed over a 2-year period. This improved significantly from baseline in both groups across all timepoints, although the improvements in women in the LNG-IUS group were significantly greater than those assigned usual medical treatment at 2-year follow-up.5 By 5-year follow-up, the benefit of LNG-IUS was reduced.5 Consequently, NICE also indicated that the usual medical treatments offered in ECLIPSE be considered for women unable or unwilling to use the LNG-IUS.

To the authors’ knowledge, there is no available research on medical treatment of HMB in the longer term in primary care,
beyond the 5-year data from the ECLIPSE trial. Although women’s need for treatment may be expected to change approaching menopause, further evidence is needed to help inform patient and clinical decision making. The primary objective of this study was to assess continuation rates of medical treatments, and rates of surgical interventions, in women 10 years after initial management for HMB in primary care.

**METHOD**

The ECLIPSE trial ended from a regulatory perspective at 5-year follow-up. However, data collection continued for this prospective observational study to 10 years. The original trial randomised women between 25 and 50 years of age who presented to their GP with HMB involving at least three consecutive menstrual cycles. The randomisation and interventions used have been previously reported. Women could subsequently swap or cease their allocated treatment. The aim of the current study was to collect 10-year data from 276 women, equating to 48.3% of the 571 women originally randomised (Figure 1). This target anticipated further loss to follow-up because of the length of time elapsed since previous contact at 2 or 5 years, relocation, non-completion of questionnaire, or death. The process of recontacting and reconsenting participants is described in Supplementary Information S1.

All data were collected directly by questionnaire (paper or via link to online form). The primary outcomes were use of treatments for HMB, and the surgical interventions of hysterectomy and endometrial ablation. Generic quality of life was assessed using the Short-Form Health Survey (SF-36, version 2, with scores ranging from 0 [severely affected] to 100 [not affected]); the EuroQoL EQ-5D descriptive system (with scores ranging from −0.59 [health state worse than death] to 100 [perfect health state]); and the EQ-5D visual analogue scale (with scores ranging from 0 [worst health state imaginable] to 100 [most perfect health state imaginable]). The Sexual Activity Questionnaire (SAQ) measured pleasure (with scores ranging from 0 [lowest level] to 18 [highest level]), discomfort (with scores ranging from 0 [greatest] to 6 [none]), and frequency. The patient-reported, condition-specific Menorrhagia Multi-Attribute Scale (MMAS) at 2-year follow-up was the primary outcome for the ECLIPSE trial. As the MMAS only seeks responses in relation to current HMB, completion was optional as it was anticipated to not be relevant to the majority of women at 10-year follow-up. Originally, manual extraction of data

**How this fits in**

Heavy menstrual bleeding (HMB) is a common problem and reason to seek treatment in primary care. It is not known how women then fare in the long term, in order to inform patient and clinical decision making. To the authors’ knowledge, this research is the first to report what proportions of women may be expected to continue to use LNG-IUS (Mirena) or other medical treatments (oral tranexamic acid, mefenamic acid, combined oestrogen-progestogen, or progesterone alone), or progress to surgical intervention, a decade after GP treatment for HMB. It shows that medical treatments for women with HMB can be initiated in primary care with low subsequent rates of surgery and improvement in quality of life 10 years later.

**Figure 1. Progression of participants from the original ECLIPSE trial to the observational study. Attempts to contact women after 23 March 2020 were curtailed because of the COVID-19 pandemic (Supplementary Information S1).**
The progression of women available to be contacted from the original trial to women in the current study (hereafter called responders) are shown in Figure 1. A total of 206 women provided reconsent and returned completed 10-year follow-up data by 31 March 2020 (200 by mail, six online).

The baseline (before randomisation) characteristics of responders and those who were not followed-up are presented in Table 1. Responders were very similar to those women not followed up, with an average age of 41.9 and 41.1 years, respectively, and did not differ clinically in their initial symptoms and presentations of HMB.

Compared by two researchers with their GP-recorded data for completeness and accuracy, which was assessed as very high. Subsequent data extraction from GP records was thus deemed unnecessary unless questionnaire data were missing. However, because of COVID-19 pandemic restrictions no further GP record extraction was performed.

Characteristics of women completing 10-year follow-up were compared with all other women in the original trial cohort (those declining when recontacted or not responding to the recontact invitation). Proportions of women of different ethnicity, HMB presentations, and randomised to different types of treatment were compared using the $\chi^2$-test. Age in years, body mass index, blood pressure, and questionnaire scores (SF-36, EQ-5D, MMAS, SAQ) in the groups were compared using either Student’s $t$-test for normally distributed variables or the Mann–Whitney test otherwise. Imputation methods for data missing from the SF-36 and SAQ are described in Supplementary Information S1.

RESULTS

The progression of women available to be contacted from the original trial to women in the current study (hereafter called responders) are shown in Figure 1. A total of 206 women provided reconsent and returned completed 10-year follow-up data by 31 March 2020 (200 by mail, six online).

The baseline (before randomisation) characteristics of responders and those who were not followed-up are presented in Table 1. Responders were very similar to those women not followed up, with an average age of 41.9 and 41.1 years, respectively, and did not differ clinically in their initial symptoms and presentations of HMB.

Table 1. Characteristics and questionnaire scores at baseline (before randomisation in original trial) between responders and women not followed-up at 10 years

| Characteristic                        | All women followed-up at 10 years (n=206) | All women not followed-up (n=365) |
|--------------------------------------|------------------------------------------|----------------------------------|
| Age at start, years                  |                                           |                                  |
| Mean (SD)                            | 41.9 (4.9)                               | 41.1 (5.4)                       |
| Age ≥35 years, n (%)                 | 188 (91.2)                               | 324 (88.7)                      |
| Ethnicity, n (%)                     |                                           |                                  |
| White                                | 178 (86.4)                               | 293 (80.2)                      |
| Asian                                | 11 (5.3)                                 | 40 (10.9)                       |
| Black                                | 9 (4.4)                                  | 21 (5.7)                        |
| Other                                | 8 (3.8)                                  | 11 (3.0)                        |
| BMI, kg/m²                           |                                           |                                  |
| Mean (SD)                            | 29.4 (6.4)                               | 29.1 (6.4)                      |
| BMI ≥25, n (%)                       | 146 (70.8)                               | 255 (69.9)                      |
| Blood pressure                       |                                           |                                  |
| Systolic blood pressure, mean (SD)   | 129.7 (17.0)                             | 128.5 (16.3)                    |
| Diastolic blood pressure, mean (SD)  | 78.8 (10.2)                              | 78.7 (10.5)                     |
| Presentation to primary care for HMB, n (%) |                                  |                                  |
| Initial                              | 157 (76.2)                               | 279 (76.4)                      |
| Subsequent                           | 49 (23.8)                                | 86 (23.6)                       |
| Duration of HMB >1 year              | 164 (79.6)                               | 296 (81.1)                      |
| Menstrual pain                       | 151 (73.3)                               | 273 (74.8)                      |
| Contraception requirement            | 35 (16.9)                                | 75 (20.5)                       |
| Copper or non-hormonal coil          | 7 (3.4)                                  | 12 (3.3)                        |
| Treatment at randomisation, n (%)    |                                           |                                  |
| LNG-IUS                              | 110 (53.4)                               | 175 (47.9)                      |
| Usual medical treatments             | 96 (46.6)                                | 190 (52.1)                      |
| Questionnaire scores, mean (SD) n    |                                           |                                  |
| SF-36                                |                                          |                                  |
| Physical functioning                 | 82.5 (19.4)                              | 76.2 (24.6)                     |
| Physical role                        | 71.7 (24.3)                              | 69.6 (26.3)                     |
| Emotional role                       | 72.0 (24.9)                              | 204                             |
| Social functioning                   | 65.7 (23.7)                              | 61.9 (26.0)                     |
| Mental health                        | 60.7 (19.9)                              | 59.1 (19.5)                     |
| Energy and vitality                  | 40.8 (21.9)                              | 40.7 (20.9)                     |
| Pain                                 | 48.5 (22.6)                              | 45.6 (22.3)                     |
| Perception of general health         | 62.2 (21.8)                              | 60.2 (21.7)                     |
| EuroQol EQ-5D                        | 0.769 (0.228)                            | 0.714 (0.276)                   |
| Descriptive system                   | 71.6 (18.9)                              | 69.0 (19.7)                     |
| EQ-5D visual analogue scale          | 10.5 (5.0)                               | 11.1 (4.9)                      |
| Discomfort                           | 4.8 (1.4)                                | 4.5 (1.7)                       |
| Menorrhagia Multi-Attribute Score    | 42.8 (19.4)                              | 39.7 (21.8)                     |

*If information was partially missing but over half of questions in a domain were answered, the average score of the responses was used, otherwise they were classed as missing. The mean scores and number of contributing participants are slightly different from the original ECLIPSE trial because of this method. BMI = body mass index. HMB = heavy menstrual bleeding. LNG-IUS = levonorgestrel-releasing intrauterine system. SD = standard deviation. SF-36 = 36-item Short-Form Health Survey.
Table 2: Menopausal status and reported treatments for HMB among all responders, and by original ECLIPSE trial allocations over 10-year follow-up period

| Menopausal status                | All responders, n (%) (n = 206) | Allocated to LNG-IUS, n (%) (n = 110) | Allocated to usual medical treatment, n (%) (n = 96) |
|----------------------------------|---------------------------------|--------------------------------------|-----------------------------------------------|
| Premenopausal                    | 32 (15.5)                       | 16 (15.5)                            | 16 (16.6)                                     |
| Postmenopausal                   | 106 (51.5)                      | 54 (49.1)                            | 52 (54.1)                                     |
| Undergone hysterectomy           | 34 (16.5)                       | 18 (16.4)                            | 16 (16.6)                                     |
| Perimenopausal or uncertain      | 32 (15.5)                       | 21 (19.1)                            | 11 (11.4)                                     |
| Missing                          | 2 (0.9)                         | 1 (0.9)                              | 1 (1.0)                                       |
| Using menopausal hormone therapy | 28 (13.6)                       | 16 (14.5)                            | 12 (12.5)                                     |
| Still experiencing heavy menstrual bleeding | 12 (5.8)                   | 6 (5.5)                              | 6 (6.3)                                       |
| Using LNG-IUS at response to 10-year follow-up | 56 (27.2)          | 38 (34.5)                            | 18 (18.8)                                     |

Classes of treatments used between 5 and 10 years

| Treatment                        | All responders, n (%) (n = 206) | Allocated to LNG-IUS, n (%) (n = 110) | Allocated to usual medical treatment, n (%) (n = 96) |
|----------------------------------|---------------------------------|--------------------------------------|-----------------------------------------------|
| LNG-IUS                          | 67 (32.5)                       | 47 (42.7)                            | 20 (20.8)                                     |
| Usual medical treatment          | 29 (14.1)                       | 10 (9.1)                             | 19 (19.8)                                     |
| LNG-IUS and usual medical treatment | 21 (10.2)                  | 11 (10.0)                            | 10 (10.4)                                     |
| None                             | 89 (43.2)                       | 42 (38.2)                            | 47 (48.9)                                     |

Standard medical treatments used between 5 and 10 years

| Treatment                        | All responders, n (%) (n = 206) | Allocated to LNG-IUS, n (%) (n = 110) | Allocated to usual medical treatment, n (%) (n = 96) |
|----------------------------------|---------------------------------|--------------------------------------|-----------------------------------------------|
| Tranexamic acid                  | 24 (11.6)                       | 7 (6.4)                              | 17 (17.7)                                     |
| Mefenamic acid                   | 6 (2.9)                         | 3 (2.7)                              | 3 (3.1)                                       |
| Norethisterone                   | 13 (6.3)                        | 4 (3.6)                              | 9 (9.3)                                       |
| Desogestrel                      | 3 (1.4)                         | 0                                   | 3 (3.1)                                       |
| Oral contraceptives              | 8 (3.9)                         | 3 (2.7)                              | 5 (5.2)                                       |
| Medroxyprogesterone acetate injection | 1 (<1)                    | 1 (<1)                               | 0                                             |
| Naproxen                         | 1 (<1)                          | 0                                   | 1 (<1)                                       |

Surgical intervention for HMB

| Procedure                        | All responders, n (%) (n = 206) | Allocated to LNG-IUS, n (%) (n = 110) | Allocated to usual medical treatment, n (%) (n = 96) |
|----------------------------------|---------------------------------|--------------------------------------|-----------------------------------------------|
| Hysterectomy                     | 34 (16.5)                       | 18 (16.4)                            | 16 (16.6)                                     |
| Endometrial ablation             | 26 (12.6)                       | 10 (9.1)                             | 16 (16.6)                                     |

HMB = heavy menstrual bleeding. LNG-IUS = levonorgestrel-releasing intrauterine system.

Allocation to different treatments was balanced across both groups of women: 110 of 206 (53.4%) responders and 175 of 365 (47.9%) of women not followed up were allocated to LNG-IUS. Responders and those not followed up also had similar baseline scores for SF-36, EQ-5D, and SAQ, with no domains showing a statistically significant difference (Table 1). Average scores at baseline for MMAS were slightly higher for women responding at 10 years (42.8 versus 39.7), and the difference was not statistically significant. The 206 responders had a mean age at response to the 10-year follow-up of 53.7 years (SD 5.1 years) and 178 (86.4%) were of White ethnicity. Among these, 110 were originally allocated to the LNG-IUS and 96 were allocated to usual medical treatment. At the time of completing the 10-year follow-up questionnaire, 106 (51.5%) women had reached menopause (defined for the responders as having experienced no menstrual bleeding for at least 1 year) and 34 (16.5%) had had a hysterectomy (Table 2). Twelve women (5.8%) were still experiencing HMB and did not consider themselves menopausal.

Between 5 and 10 years of follow-up, a substantial proportion of women (89, 43.2%) reported not taking treatments for HMB. However, 88 (42.7%) of women used LNG-IUS (67 women used only LNG-IUS, and 21 used LNG-IUS in combination with usual medical treatment). The proportions using LNG-IUS, alone or in combination, were higher for women initially allocated to LNG-IUS than to usual medical treatment (58/110 women [52.7%] and 30/96 women [31.3%, respectively]). Overall, 56 (27.2%) women reported they were using LNG-IUS at the time of response to the 10-year follow-up (including 34.5% [38/110] of women originally allocated to LNG-IUS and 18.8% [18/96] of women originally allocated to medical treatments). Table 2 shows the reported treatments by original randomised allocation. There were no statistically significant differences in treatments between the two randomised groups for any menopausal or treatment category.

Table 3 reports the distributions of SF-36, EQ-5D, and SAQ scores, for all responders and by the original randomised allocation, 10 years after randomisation. There were no statistically significant differences between the randomised groups in any domain of the three questionnaires. Only 13 responders, 12 of whom described their bleeding as heavy, completed the MMAS questionnaire, so distributions were not calculated, nor groups compared. The SAQ was completed by 116 of the 206 responding women, indicating at least 56.3% of women were sexually active.

Table 4 presents scores for these three questionnaires by randomised group at baseline and at 10-year follow-up, including only those women who completed questionnaires at both timepoints. There were improvements over time in SF-36 scores in all domains, except general health perception and physical functioning, and in EQ-5D scores. These improvements occurred in both groups, with small and statistically insignificant differences between groups.

Of the 206 women, 40 were not in an intimate relationship and 116 reported via the SAQ that they were sexually active. There was a clear deterioration within the discomfort domain of the SAQ, although with no evidence of a difference between groups compared.
Table 3. Questionnaire scores at 10 years among all responders, and by original ECLIPSE trial allocations

|                                | All responders, mean (SD) n | Allocated to LNG-IUS, mean (SD) n | Allocated to usual medical treatment, mean (SD) n |
|--------------------------------|-----------------------------|----------------------------------|-----------------------------------------------|
| SF-36                          |                             |                                  |                                               |
| Physical functioning            | 80.2 (26.2) 205             | 81.4 (24.9) 110                  | 78.8 (27.7) 95                                |
| Physical role                   | 78.4 (28.6) 204             | 80.1 (26.2) 109                  | 76.4 (31.1) 95                                |
| Emotional role                  | 79.4 (27.5) 204             | 79.3 (26.4) 109                  | 79.5 (28.9) 95                                |
| Social functioning              | 74.7 (25.8) 206             | 75.5 (25.2) 110                  | 73.8 (26.6) 96                                |
| Mental health                   | 68.6 (21.5) 205             | 68.1 (21.1) 110                  | 69.2 (22.0) 95                                |
| Energy and vitality             | 48.9 (10.2) 205             | 48.3 (8.8) 110                   | 49.5 (11.6) 95                                |
| Pain                            | 63.4 (24.6) 206             | 64.3 (23.9) 110                  | 62.4 (25.9) 96                                |
| Perception of general health    | 55.4 (9.6) 206              | 55.9 (10.3) 110                  | 56.9 (8.7) 95                                 |
| EuroQoL EQ-5D                   |                             |                                  |                                               |
| Descriptive system              | 0.748 (0.266) 204           | 0.757 (0.249) 110                | 0.736 (0.286) 94                              |
| Visual analogue scale           | 73.4 (20.7) 176             | 74.9 (19.8) 93                   | 71.8 (21.6) 83                                |
| Sexual Activity Questionnaire   |                             |                                  |                                               |
| Pleasure                        | 11.2 (4.6) 116              | 11.5 (4.6) 62                    | 10.9 (4.6) 54                                 |
| Discomfort                      | 2.01 (1.99) 116             | 2.19 (2.09) 62                   | 1.80 (1.87) 54                                 |

LNG-IUS = levonorgestrel-releasing intrauterine system. SD = standard deviation. SF-36 = 36-item Short-Form Health Survey.

Figure 2. Surgery-free time for all responders by original ECLIPSE trial allocations. LNG-IUS = levonorgestrel-releasing intrauterine system.

DISCUSSION
Summary
This study shows medical treatments for women with HMB can be initiated in primary care with improvement in quality of life and high likelihood of avoiding surgery 10 years later. Among women, typically presenting with HMB in their early forties, this study found that half reach the menopause in the ensuing decade and over 40% may be expected to cease medical treatments over this time. However, a similar proportion (42.7%) continue to use LNG-IUS alone or in combination with other oral treatments, and almost 30% were using LNG-IUS after 10 years.

Relatively low rates of surgical intervention were sustained at 29% after 10 years, modestly increased from those at 5 (around 20%) and 2 (around 10%) years after commencing treatment in primary care.1,3 Women initially treated with LNG-IUS were slightly less likely to need surgical intervention than those commenced on standard medical treatments, however, this was not statistically or clinically significant. There were improvements over time in generic quality-of-life scores in both women who were initially allocated LNG-IUS or to other usual medical treatment, but with no evidence of any significant differences between the two original groups.

Strengths and limitations
This research has ascertained outcomes in women a decade after initial treatment for HMB in primary care, following participation in the largest trial of medical treatments for HMB.1,3 Responses were achieved from 206 women, 206/571, 36.1% of the original trial population and 206/490, 42.0% of those potentially available for recontact after 10 years. Although this was lower than anticipated because of difficulties during the allocation groups, but no changes were seen within the pleasure domain.

Surgical interventions
Over the 10-year follow-up period, there were 60 of 206 (29.1%) women who had had surgical intervention, including hysterectomy (n=34, 16.5%) or endometrial ablation (n=26, 12.6%). No woman had both procedures and no one who had a surgical procedure reported HMB at 10 years. The cumulative rate of surgery was slightly lower in women initially allocated to LNG-IUS (28/110 women, 25.5%) compared with those allocated to standard medical treatment (32/96, 33.3%), (data not shown) in the ECLIPSE trial. Considering the opposite outcome, the surgery-free rate, including all data collected over a median of 11.2 years, the cumulative surgery-free rate was 74% for LNG-IUS and 65% for usual medical treatment, shown in Figure 2, and the difference was not statistically significant (hazard ratio 0.73, 95% confidence = 0.44 to 1.21, \( P = 0.22 \)).
Table 4. Questionnaire scores at baseline and 10 years of follow-up

| Questionnaire | Usual medical treatment | LNG-IUS treatment | Change within group, mean (95% CI) | 10-year follow-up, mean (95% CI) | P-value | Usual medical treatment | LNG-IUS treatment | Difference between groups over 10 years, mean (95% CI) | P-value |
|---------------|-------------------------|-------------------|-----------------------------------|---------------------------------|---------|-------------------------|-------------------|-----------------------------------------------------|---------|
| SF-36 | | | | | | | | | |
| Physical functioning | 84.0 (81.5 to 86.5) | 80.7 (77.8 to 83.6) | 81.2 (78.2 to 84.2) | 78.8 (75.5 to 82.1) | –0.9 (–4.4 to 2.6) | 0.786 | -2.8 (–5.7 to 0.2) | 0.220 | –1.9 (–4.9 to 1.1) | 0.409 |
| Physical role | 74.0 (71.0 to 76.9) | 69.1 (65.9 to 72.2) | 79.9 (76.8 to 83.0) | 76.4 (72.9 to 79.9) | –1.3 (–5.4 to 2.8) | 0.760 | 6.0 (2.7 to 9.3) | 0.038 | 7.3 (4.2 to 10.4) | 0.019 |
| Emotional role | 72.4 (69.4 to 75.5) | 71.2 (68.1 to 74.4) | 79.8 (76.8 to 82.9) | 79.5 (76.1 to 82.8) | –0.8 (–4.9 to 3.2) | 0.844 | 7.4 (4.2 to 10.6) | 0.007 | 8.2 (4.9 to 11.6) | 0.003 |
| Social functioning | 67.2 (64.4 to 70.0) | 64.1 (60.9 to 67.3) | 75.2 (72.2 to 78.3) | 73.8 (70.6 to 77.1) | –1.7 (–5.7 to 2.3) | 0.804 | 8.0 (5.0 to 11.0) | <0.001 | 9.8 (6.2 to 13.4) | <0.001 |
| Mental health | 61.7 (59.0 to 64.4) | 60.0 (57.3 to 62.8) | 68.1 (65.3 to 70.9) | 69.2 (66.2 to 72.1) | –2.8 (–6.1 to 0.5) | 0.331 | 6.3 (3.7 to 9.0) | <0.001 | 9.1 (6.2 to 12.1) | <0.001 |
| Energy and vitality | 41.6 (38.8 to 44.4) | 40.0 (37.0 to 43.0) | 48.3 (46.5 to 50.1) | 49.5 (47.4 to 51.7) | –2.8 (–6.4 to 0.7) | 0.392 | 6.7 (3.8 to 9.6) | <0.001 | 9.5 (6.5 to 12.6) | <0.001 |
| Pain | 49.0 (46.1 to 51.9) | 47.9 (44.9 to 50.9) | 64.1 (61.2 to 67.1) | 62.4 (59.2 to 65.6) | 0.7 (–3.2 to 4.5) | 0.866 | 15.1 (12.0 to 18.3) | <0.001 | 14.5 (11.1 to 17.8) | <0.001 |
| Perception of general health | 63.5 (60.7 to 66.3) | 60.7 (57.7 to 63.6) | 56.0 (54.0 to 57.9) | 54.9 (53.0 to 56.7) | –1.9 (–5.2 to 1.4) | 0.564 | –7.5 (–10.4 to –4.7) | <0.001 | –5.8 (–8.7 to –3.0) | <0.001 |

aScores are only calculated for women who provided both baseline and 10-year data, so the baseline scores are slightly lower. **P-values:** The original trial and current study follow-up population reflect the ethnic diversity of England and Wales when women were recruited (87% White, 13% Black/Asian/Other in 2011 UK census). However, it is recognised that further research with women from Black and ethnic minority communities is needed as HMB experiences may differ, especially given the higher prevalence of fibroids in Black women.

The original intention had been to collect data from GP records, but cross-checking against women’s self-reported data suggested this did not add value. As GP practices then became inaccessible to researchers during the COVID-19 pandemic, the potential for missing data exists but is probably limited. Women’s own knowledge and reporting of whether they had an LNG-IUS in situ or not, their use of other oral medical treatments, their perception of being perimenopausal or of having surgery, is likely to be accurate and using this in the current study was the most realistically achievable option. Participating women’s qualitative experiences of HMB and influences on their treatment over time will be reported separately in a future article.

Comparison with existing literature

To the authors’ knowledge, this study is the first to report outcomes a decade after commencing medical treatment for HMB in primary care. Evidence from...
Implications for practice

The original ECLIPSE trial recruited women from the general population who had HMB that was affecting their lives, who chose to present to their GP with this problem, and who were clinically assessed as appropriate for, and who wanted to have, medical treatment. This assessment and the range of medical treatments used (LNG-IUS or other standard medical treatments) reflected real-life practice and remains the range of choices available to women of any age and their GP in the community setting, according to women’s individual needs and preferences. This is consistent with current updated NICE guidance for initial management of HMB.1

The sustained low rates of progression to surgical intervention observed, and general improvement in quality of life, 10 years from women’s initial presentation, underline the importance and value of initiating medical management of women’s HMB in primary care, where most women seek help from health services. Avoiding referrals to secondary care is likely to reduce operative intervention rates. The findings provide helpful information for women and GPs on what to expect in the longer term from starting treatments for HMB and to inform individual decision making. This includes women’s chances of surgery, of continuing or ceasing medical treatments, and an accurate estimate of 10-year retention of LNG-IUS.

Wider public awareness is also needed to encourage women to seek help for HMB if it is affecting their lives, as they are likely to benefit from treatments commenced in the community setting. Ongoing care should ensure clinical willingness to continue review of women’s response, their working diagnosis, need for further investigation or different treatment, or surgical options over time. This should include counselling in those women considering removal or renewal of LNG-IUS at 5 years so that they may continue to benefit and avoid surgery.

In conclusion, the study provides a helpful new indication of expected proportions of women continuing to use or not use treatments for HMB, or progressing to surgical intervention, and of the significant proportion of women using LNG-IUS after a decade. Medical treatments for women with HMB can be initiated in primary care with low rates of surgical intervention and improvement in quality of life observed 10 years later. The study supports current NICE recommendations1 on medical management of HMB, and confirms many women with HMB do not require surgery as there are less invasive and acceptable alternatives.
REFERENCES

1. National Institute for Health and Care and Excellence. Heavy menstrual bleeding: assessment and management. NG88. London: NICE, 2018. https://www.nice.org.uk/guidance/ng88 (accessed 10 Oct 2022).

2. Janssen CAH, Scholten PC, Heintz APM. Reconsidering menorrhagia in gynecological practice: Is a 30-year-old definition still valid? Eur J Obstet Gynecol Reprod Biol 1998; 78(1): 69–72.

3. Gupta J, Kai J, Middleton L, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013; 368(2): 128–137.

4. Shaw RW, Brickley MR, Evans L, Edwards MJ. Perceptions of women on the impact of menorrhagia on their health using multi-attribute utility assessment. Br J Obstet Gynaecol 1998; 105(11): 1155–1159.

5. Kai J, Middleton L, Daniels J, et al. Usual medical treatments or levonorgestrel-IUS for women with heavy menstrual bleeding: long-term randomised pragmatic trial in primary care. Br J Gen Pract 2016; DOI: https://doi.org/10.3399/bjgp16X681577.

6. Thirlaway K, Fallowfield L, Cuzick J. The Sexual Activity Questionnaire: a measure of women’s sexual functioning. Qual Life Res 1996, 5(1): 81–90.

7. Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188(1): 100–107.

8. Heliövaara-Peippo S, Hurskainen R, Teperi J, et al. Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial. Am J Obstet Gynecol 2013; 209(6): S35.e1–S35.e14.

9. Bhattacharya S, Middleton L, Tsourapas A, et al. Hysterectomy, endometrial ablation and Mirena for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis. Health Technol Assess 2011; 15(19): i–ii, 252.

10. Meaidi A, Kuh Skals R, Alexander Gerds T, et al. Decline in Danish use of oral tranexamic acid with increasing use of the levonorgestrel-releasing intrauterine system: a nationwide drug utilization study. Contraception 2020; 101(5): 321–326.

11. Van den Brink MJ, Saatink AL, Groenhof F. Incidence and treatment of heavy menstrual bleeding in general practice. Fam Pract 2013; 34(6): 673–678.